JP2020521797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521797A5 JP2020521797A5 JP2019566199A JP2019566199A JP2020521797A5 JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5 JP 2019566199 A JP2019566199 A JP 2019566199A JP 2019566199 A JP2019566199 A JP 2019566199A JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- seq
- treatment
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174323 | 2017-06-02 | ||
| EP17174323.0 | 2017-06-02 | ||
| EP17196949.6 | 2017-10-17 | ||
| EP17196949 | 2017-10-17 | ||
| PCT/EP2018/064445 WO2018220169A1 (en) | 2017-06-02 | 2018-06-01 | Anti-cancer combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521797A JP2020521797A (ja) | 2020-07-27 |
| JP2020521797A5 true JP2020521797A5 (enExample) | 2021-07-26 |
Family
ID=62386492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566199A Pending JP2020521797A (ja) | 2017-06-02 | 2018-06-01 | 抗がん剤組み合わせ治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11198726B2 (enExample) |
| EP (1) | EP3630822A1 (enExample) |
| JP (1) | JP2020521797A (enExample) |
| KR (1) | KR20200013231A (enExample) |
| CN (1) | CN110691790A (enExample) |
| AU (1) | AU2018277227A1 (enExample) |
| BR (1) | BR112019022074A2 (enExample) |
| CA (1) | CA3061053A1 (enExample) |
| CL (1) | CL2019003430A1 (enExample) |
| IL (1) | IL270905A (enExample) |
| MX (1) | MX2019014199A (enExample) |
| PH (1) | PH12019502692A1 (enExample) |
| WO (1) | WO2018220169A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016075035A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| JP7805363B2 (ja) | 2020-11-02 | 2026-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| CN116744969A (zh) | 2020-11-04 | 2023-09-12 | 海德堡医药研究有限责任公司 | 用于癌症疗法的包含免疫检查点抑制剂与抗体-鹅膏毒素缀合物的组合的组合物 |
| MX2023011031A (es) | 2021-03-19 | 2023-12-14 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo especificos de linfocitos b. |
| EP4400512A4 (en) * | 2021-09-10 | 2025-07-23 | Soter Biopharma Pte Ltd | ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE |
| JP2025533028A (ja) * | 2022-09-28 | 2025-10-03 | 科▲興▼生物制▲薬▼股▲ふん▼有限公司 | Ａｎｇ－２を認識できる抗体または抗原結合断片及びｖｅｇｆとａｎｇ－２を同時に認識できる二重抗体 |
| AU2023374571A1 (en) | 2022-11-01 | 2025-04-03 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2026083295A1 (en) * | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PL2831111T3 (pl) * | 2012-03-30 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Cząsteczki wiążące Ang2 |
| US20140093498A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| WO2014049100A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EP3286217A1 (en) | 2015-04-23 | 2018-02-28 | F. Hoffmann-La Roche AG | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1 |
| WO2016170039A1 (en) * | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| CN109069638B (zh) * | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| EP3848393A1 (en) * | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
| BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
-
2018
- 2018-06-01 BR BR112019022074-7A patent/BR112019022074A2/pt not_active IP Right Cessation
- 2018-06-01 KR KR1020197035427A patent/KR20200013231A/ko not_active Withdrawn
- 2018-06-01 JP JP2019566199A patent/JP2020521797A/ja active Pending
- 2018-06-01 EP EP18727819.7A patent/EP3630822A1/en not_active Ceased
- 2018-06-01 MX MX2019014199A patent/MX2019014199A/es unknown
- 2018-06-01 CA CA3061053A patent/CA3061053A1/en active Pending
- 2018-06-01 AU AU2018277227A patent/AU2018277227A1/en not_active Abandoned
- 2018-06-01 WO PCT/EP2018/064445 patent/WO2018220169A1/en not_active Ceased
- 2018-06-01 CN CN201880036511.5A patent/CN110691790A/zh active Pending
- 2018-06-01 US US15/995,375 patent/US11198726B2/en active Active
-
2019
- 2019-11-25 CL CL2019003430A patent/CL2019003430A1/es unknown
- 2019-11-25 IL IL270905A patent/IL270905A/en unknown
- 2019-11-28 PH PH12019502692A patent/PH12019502692A1/en unknown
-
2021
- 2021-11-08 US US17/520,748 patent/US20220340651A1/en not_active Abandoned